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Abstract
Calcium ions play a critical role in neuronal cell death. Pigment epithelium-derived factor (PEDF) is a promising
neuroprotective protein for photoreceptor cells but the mechanisms mediating its effects against retinal degeneration
are still not well characterized. We addressed this question in the rd1 degenerating mouse retina that bears a mutation
in the Pde6b gene encoding one subunit of the phosphodiesterase enzyme. Loss of phosphodiesterase activity in rod
photoreceptor cells increases cyclic guanosine monophosphate (cGMP) levels leading to a rise in intracellular calcium.
Short-term treatments with recombinant human PEDF protein decreased intracellular calcium in photoreceptors
in vivo. Taking advantage of calcium pump blockers, we defined that PEDF signaling acts on PMCA calcium pumps to
lower intracellular calcium. PEDF restrained cell death pathways activated by high calcium levels and engaging
calpains, BAX and AIF. The neurotrophic effects were mediated by the PEDF receptor (PEDF-R), encoded by the PNPLA2
gene. Finally, peptides containing the neurotrophic domain of PEDF targeted these same cell death pathways in vivo.
The findings reveal rescue from death of degenerating photoreceptor cells by a PEDF-mediated preservation of
intracellular calcium homeostasis.
Introduction
Retinal degeneration is an inherited disease linked to
mutations in >100 genes and this genetic heterogeneity
hampers the development of a cure. Although gene
therapy was developed for specific forms of the disease,
unfortunately, only a limited number of patients can
benefit from such an exquisite type of therapy. In recent
years, we and others have reported several lines of evi-
dence for common molecular mechanisms that are acti-
vated during photoreceptor cell death in different models
of the disease1,2. The application of neurotrophic factors
to target common cell death mechanisms is an attractive
strategy for treating more than only one form of this
group of diseases. Neuroprotective activities of several
molecules were reported in different models of retinal
degeneration and in clinical trials3–14. However, the use of
neuroprotective factors requires deep knowledge on the
molecular mechanism underlying their effects to better
interpret the outcomes of the treatment.
Pigment epithelium-derived factor (PEDF) is a protein
implicated in the survival and normal function of photo-
receptor cells15. PEDF is found in the healthy human eye
and its levels are altered in eyes affected by retinal
degenerative processes16–20. In human and murine eyes
with retinal degeneration, PEDF levels are reduced and in
animal models of retinopathies PEDF treatments protect
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the neuroretina, attenuate angiogenesis and neovessel
invasion, and prevent loss of visual function15,16,18,20,21. In
the retina, PEDF is preferentially secreted from the apical-
lateral side of the retinal pigment epithelium (RPE)
toward the photoreceptors, where it acts on photo-
receptor morphogenesis, neurite outgrowth and survi-
val22,23. PEDF also promotes retinal stem cell expansion
in vitro24. PEDF is a secreted glycoprotein bearing sepa-
rated functional domains for neurotrophic and anti-
angiogenic effects25–28. Photoreceptors and ganglion cells
in the retina express receptors for PEDF29 and one of
these is PEDF receptor (PEDF-R) encoded by the patatin-
like phospholipase domain-containing 2 (PNPLA2)
gene30. PEDF-R is a phospholipase membrane protein
expressed at the surface of retinal cells and is localized at
the inner segment of the photoreceptors and, at lower
levels, also in other retinal cell types30. PEDF-R mediates
retinal cell survival activity of PEDF in vitro and
in vivo11,31.
Intravitreal injections of recombinant human PEDF
protein significantly decreased photoreceptor cell death in
rodent models of retinal degeneration caused by genetic
mutations or by light damage11,13,14,32,33. Ectopic expres-
sion of PEDF in the Royal College of Surgeons (RCS) rats
by subretinal delivery using a lentiviral system showed
that PEDF reduces nuclear translocation of apoptosis-
inducing factor (AIF), as well as increases B-cell lym-
phoma 2 (BCL2) protein levels in photoreceptors12. We
recently showed that peptides derived from the domain of
human PEDF protein that confer the functions associated
with neuronal differentiation and survival (residues
98–114) are strongly neuroprotective when injected into
the eye of a murine model of retinal degeneration, the
retinal degeneration 1 (rd1) mouse, and act through
PEDF-R11. Studies published so far indicated that PEDF is
a promising neuroprotective protein for retinal degen-
eration but the mechanisms mediating PEDF effects in the
retina are still not well characterized. This lack of infor-
mation hampers the molecular and pharmacological
evaluation of the beneficial effects of PEDF as a pro-
spective therapeutic agent for the retina.
To better characterize targets of the protective activity
of PEDF in photoreceptors, we analyzed cell death path-
ways in rd1 mutant retinas by treatment with purified
recombinant PEDF protein and short PEDF peptide
fragments11 via intravitreal injections. The rd1 mouse
model bears a mutation in the Pde6b gene and is asso-
ciated with increased levels of cGMP due to the lack of
activity of the phosphodiesterase enzyme (PDE6)34.
cGMP, not hydrolyzed by PDE6, accumulates inside the
cells activating several intracellular signals and, among
them, provokes an influx of Ca2+ ions by binding to
cGMP-gated cation (Na+/Ca2+) channels35,36. Calpain
proteases respond to changes in intracellular Ca2+ and are
over-activated in rd1 mutant photoreceptors9,37,38. Acti-
vation of calpains triggers several downstream responses
in the rd1 mutant retina, such as activations of cathepsin
D and BAX2. AIF, a cell death executioner, exits from
mitochondria through a pore formed by BAX upon
cleavage by calpains and translocates into the nucleus
leading to chromatin fragmentation39–41. We, thus, eval-
uated intracellular calcium content and calpain activation
and we determined the levels of BAX, BCL2 and AIF
proteins after treatment with PEDF in vivo. We explored
in vitro and in vivo the role of PEDF on the extrusion of
calcium using specific Ca2+ pump inhibitors in models of
the disease. Our findings lead to discussions of a novel
pathway for the PEDF neurotrophic effects against retinal
degeneration.
Results
PEDF protects the degenerating retina by decreasing
intracellular calcium
We recently defined that doses of 6 pmol per eye of
recombinant PEDF significantly protect rd1 mutant
photoreceptor cells by lowering cell death by about 40%11.
Applying this same injection paradigm, that is, intravitreal
delivery in rd1 mice at postnatal-day 11 (PN11) and
analysis 16 h later at PN12, we assessed cell death path-
ways in the rd1 model of retinal degeneration. First we
assayed for intracellular Ca2+ content in the rd1 photo-
receptors after treatment with PEDF because retinal
degeneration in the rd1 model is characterized by influx
of Ca2+ ions35,37. Using the Fluo-4 AM fluorescent dye,
we compared PEDF-treated with contralateral mock-
treated samples by cytofluorimetric analysis. We con-
sistently found a decreased number of photoreceptors
with high intracellular Ca2+ after treatment with PEDF
(Figs. 1a, b and Supplemental figure S1 a-d). The speci-
ficity of this outcome was investigated with the use of the
P1 peptide that blocks the binding of PEDF to its receptor
PEDF-R11,31. When we co-injected PEDF with 10-fold
molar excess of the P1 interfering peptide, the PEDF
inhibitory effects on intracellular Ca2+ levels were abol-
ished (Figs. 1a, b).
Photoreceptors outer segments, where the photo-
transduction cascade is initiated, possess the cGMP-gated
channel (CNGC) for Ca2+ entrance and one Ca2+ clear-
ance pathway through the NCKX (Na+/Ca2+-K+
exchanger)42. The highest intracellular Ca2+ reservoir in
photoreceptors is the endoplasmic reticulum (ER) where
Ca2+ uptake is mediated by the sarco-ER Ca2+ ATPase
(SERCA). Ca2+ clearance from the cytosol is regulated by
SERCA and by PMCA (plasma membrane Ca2+ ATP-ase)
pumps42. We investigated if PEDF could modulate
intracellular Ca2+ by acting on any of these pumps. To
this aim, we modeled the loss-of-function of PDE6 using
661W cell cultures treated in vitro with zaprinast, a PDE6
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inhibitor that increases intracellular cGMP. Zaprinast
increased intracellular Ca2+ and also induced cell death in
661W cells (Figs. 1c, d and Supplemental Figures S1 e and
S2 a). Paralleling our in vivo findings (Fig. 1a and Kenealey
et al.11), the in vitro model showed that PEDF could
decrease intracellular calcium, as well as photoreceptor
cell death by about 40% (Figs. 1c, d and Supplemental
Figure S2 a). To identify the intracellular targets of PEDF,
we blocked one by one the three clearance pumps/
exchangers with specific drugs. We first tested 3′,4′-
dichlorobenzamyl (BZ), a blocker of NCKX pumps, and
caloxin (CLX), a blocker of PMCA, and defined con-
centrations able to increase intracellular calcium and thus
to block the pumps (Supplemental Figure S2 b). We also
tested thapsigargin (TG), a blocker of SERCA, by analysis
of activation of the ER stress marker PERK, which
Fig. 1 Decreased intracellular Ca2+ after treatment with PEDF. a Cytofluorimetric analysis of Ca2+, as evaluated by Fluo-4 AM labeling, in rd1
mutant photoreceptors not treated (MOCK) or treated with 6 pmol of PEDF (PEDF) or co-treated with PEDF and 10 molar excess of P1 peptide (PEDF
+ P1). As control, we show data from wild-type photoreceptors (WT). The levels of calcium (medium fluorescence intensity, MFI) in cells (events) were
reduced in the presence of PEDF (PEDF vs MOCK and PEDF vs PEDF+ P1). b Ratio of photoreceptor cells with high levels of Ca2+ (see parameters in
Supplemental figure S1), as evaluated by Fluo-4 AM labeling and cytofluorimetric analysis, in PEDF treated compared with contralateral eyes treated
either with vehicle (MOCK) or with PEDF and 10 molar excess of P1 peptide (PEDF+ P1). Data are shown as means ± SD (N= 4–9; ***P ≤ 0.001). c
Cytofluorimetric analysis of Ca2+, as evaluated by Fluo-4 AM labeling, in 661W cells stressed with 500 μM zaprinast (ZAP), to block PDE6 function and
to mimic the rd1 mutation, and in 661W cells treated with Zaprinast and PEDF (ZAP+ PEDF). As control, we show data from cells unstained with
Fluo-4 AM (US) or not treated with zaprinast (NT). The levels of calcium (medium fluorescence intensity, MFI) in cells (events) were reduced in the
presence of PEDF in cells stressed with zaprinast (ZAP+ PEDF vs ZAP). d 661W cells were stressed with 500 μM zaprinast (ZAP) that caused cell death,
as assessed by TUNEL staining. PEDF neuroprotective effects were maintained after exposure to 100 μM 3′,4′-dichlorobenzamyl (BZ) or 200 nM
Thapsigargin (TG). PEDF neuroprotection was reduced when cells were exposed to 10 μM caloxin (CLX). The percentage of PEDF neuroprotection is
reported above the P-value. Data are shown as means ± SD (N= 5–8; *** P ≤ 0.001). e Sections of rd1 mutant retinas either treated with vehicle
(MOCK) or with 6 pmol of PEDF (PEDF) or with 100 μM of CLX or with PEDF and CLX (PEDF+ CLX). The outer nuclear layer of the retina, containing
the photoreceptor nuclei (blue), is shown after TUNEL staining (red, arrows). Scale bar: 20 μm. f Quantification of cell death in rd1 mutant retinas
either treated with vehicle (MOCK) or with 6 pmol of PEDF (PEDF) or with 100 μM of CLX or with PEDF and CLX (PEDF+ CLX). The percentage of
neuroprotection is reported above the P-value. Data are shown as means ± SD (N= 4–6; ***P ≤ 0.001)
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resulted phosphorylated (Supplemental Figure S2 c). It is
worth noting that the three drugs at the tested con-
centrations did not increase 661W cell death by them-
selves after 16 h of treatment (data not shown) and
modestly increased death in cells that had been stressed
with zaprinast (Fig. 1d). Interestingly, only CLX, which
blocks PMCA, significantly attenuated the PEDF-
mediated neuroprotective effects suggesting that PEDF
may act through these plasma membrane pumps (Fig. 1d).
The block of SERCA by TG, and NCKX by BZ, did not
affect PEDF neuroprotection (Fig. 1d), discarding these
pumps from mediating Ca2+ clearance, at least in this
model. We confirmed the effects of PEDF on PMCA in an
alternative in vitro model, that is, rod-like cells differ-
entiated from rd1 mutant neurospheres37. PEDF pro-
tected rd1 mutant rod-like cells from cell death and CLX
interfered with the neuroprotective activity (Supplemental
Figure S3). To examine the direct effect of PEDF on the
regulation of intracellular Ca2+, we treated 661W cells
with A23187, an ionophore that allows calcium influx, as
also shown in retinas in vivo43. PEDF strongly reduced cell
death in A23187-treated 661W cells and, most impor-
tantly, the PMCA blocker CLX interfered with the pro-
tective activity of PEDF (Supplemental Figure S2 d).
To confirm in vivo that PEDF decreases [Ca2+]i by
targeting PMCA, PEDF was intravitreally co-injected with
CLX in rd1 mutant eyes. We defined that 100 μM con-
centration of CLX was able in vivo to increase [Ca2+]i in
photoreceptors with low toxicity (Supplemental Fig-
ure S4). When PEDF was co-injected with CLX, the
neuroprotective activity was significantly reduced
(Figs. 1e, f).
These results indicated that PEDF acted on PMCA to
reduce intracellular calcium at early steps of the rod
photoreceptor cell death cascade.
Calpain activation is restrained by PEDF
After defining that PEDF reduces intracellular calcium,
we evaluated activation of calcium-dependent proteases
calpains by an in situ calpain activity assay2,9,37,38 and by
assessing the cleavage of αII-spectrin, a substrate for
calpains44. PEDF attenuated calpain activation in rd1
mutant photoreceptors and co-injection with the P1
blocking peptide at 10-fold molar excess to PEDF reversed
the effect (Figs. 2a, b). Reduced calpain activity after
exposure to PEDF was confirmed by the decrease of the
amount of the 145–150 kDa fragments of αII-spectrin
derived from calpain cleavage in rd1 mutant retinas
(Fig. 2c, asterisk, and e). Co-injection of the P1 peptide
blocked the effects of PEDF on calpain activity, implying
involvement of PEDF-R.
We speculated that the attenuated calpain activation
was a result of increased levels of calpastatin, its endo-
genous inhibitor45. Although we observed decreased
calpastatin levels in the rd1 retina, as previously pub-
lished38, PEDF did not restore wild-type levels of the cal-
pain inhibitor (Figs. 2d, e and Supplemental Figures S5 a).
These results implied that the decrease of intracellular
calcium levels mediated by PEDF contributed to the
attenuation of activated calpains independent of
calpastatin.
PEDF limits activation of BAX in the degenerating retina
We assessed the activation of cathepsin D by immu-
noblotting and found that the cleaved/activated form of
cathepsin D (Fig. 3a, asterisk) was significantly decreased
after PEDF exposure when compared with mock-treated
retinas or to retinas co-injected with 10-fold molar excess
of blocking P1 peptide over PEDF (Figs. 3a, b).
Calpains and cathepsin D activate BAX, which trans-
locates to the mitochondria in the retina and in
other tissues2,46. We evaluated BAX translocation to the
mitochondrial membrane by immunoblotting of
mitochondrial-enriched protein extracts. PEDF decreased
mitochondrial BAX proteins levels, which again was
reversed with 10-fold molar excess of P1 peptide over
PEDF (Figs. 3c, d and Supplemental Figures S5 b).
Activation of BAX can be modulated also by other BH3
family members and among those the anti-apoptotic
BCL2 protein that we reported to be reduced in the rd1
retina and in other murine models of RP relative to wild-
type mice2. We evaluated BCL2 protein and found that
PEDF restored BCL2 levels and the rescue was blocked
when the P1 interfering peptide was co-injected with
PEDF (Figs. 3e, f and Supplemental Figures S5 c).
These observations implied that PEDF attenuated BAX
activation in photoreceptor cells and increased BCL2
levels. Moreover, interference of PEDF binding to PEDF-R
by the P1 peptide reversed the PEDF effects on cathepsin
D and BAX activation, as well as on BCL2 levels implying
a role for the PEDF–PEDF-R interaction in the attenua-
tion of the cell death pathway.
PEDF impairs translocation of AIF in the degenerating
retina
Calpains are proteases that cleave mitochondrial AIF, a
cell death executioner exiting from the mitochondria
through a pore formed by BAX and translocating to the
nucleus39–41. Here we performed in situ immuno-
fluorescence staining and immunoblotting of nuclear
extracts to evaluate AIF in rd1mutant retinas treated with
PEDF. The data showed that PEDF decreased AIF nuclear
levels implying that it restrained AIF nuclear translocation
in the rd1 murine model of retinal dystrophy (Figs. 4a–d
and Supplemental Figures S5 d). The effects of PEDF on
nuclear localization of AIF paralleled those on cell death
evaluated by TdT-mediated dUTP terminal nick-end
labeling (TUNEL) staining (Fig. 4b). The lack of
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reduction of AIF nuclear localization when PEDF was co-
injected with the P1 peptide inferred that this effect was
mediated by the binding to PEDF-R (Figs. 4a–d). Alto-
gether these data defined that PEDF neuroprotection
acted on the cell death pathway activated by calcium
influx and mediated by AIF activation in photoreceptor
cells.
Retinoprotective domain of 17-amino acids signals like
PEDF
We previously mapped the retinoprotective domain of
PEDF to 17-amino acids spanning between residue posi-
tions 98–114 of the human polypeptide sequence, here
called 17-mer11. We hypothesized that the 17-mer
domain mediated the effects of PEDF on the cell death
effectors activated by increased calcium. To address this
question, we intravitreally injected the 17-mer peptide or
the altered 17-mer[R99A], with no PEDF-R binding affi-
nity and neuroprotective activity, or the 17-mer[H105A],
with an enhanced PEDF-R binding affinity and neuro-
protective activity11. We found that peptides 17-mer and
17-mer[H105A] attenuated activation of calpains, BAX
and AIF, whereas they increased BCL2 levels (Figs. 5a–f),
similarly to what was observed with PEDF. In contrast, the
17-mer[R99A] peptide did not block the cell death
pathways.
These results showed that the activity of the PEDF
neurotrophic domain interfered with activation of
Fig. 2 PEDF constrains activation of calpains. a Calpain activity, as detected by exposure of frozen unfixed rd1 retina sections to a fluorescent
calpain substrate, shows a decrease in number of cells with high calpain activity (fluorescent spots in the outer nuclear layer, arrows) in retinas treated
with PEDF but not in retinas treated with PEDF and P1 blocking peptide (PEDF+ P1). ONL outer nuclear layer containing photoreceptors. Scale bar:
20 μm. b Percentages (±SD) of photoreceptors with activated calpains counted in the ONL of retinal sections passing through the optic nerve, as
shown in panel (a) (N= 5). c, d Total protein extracts from wild type (WT) and rd1 mutant mouse retinas were analyzed by immunoblots after
treatment with either vehicle (MOCK) or PEDF or PEDF and P1 blocking peptide (PEDF+ P1). The analysis with an anti-αII-spectrin antibody (SPTA2, c)
shows a decrease of the 145–150 kDa fragments resulting from calpain cleavage (asterisk) in PEDF-treated retinas. Analysis of calpastatin (CAST, d)
shows a decrease of the protein in mutant retinas (MOCK) compared with wild-type retinas but no change after treatment with PEDF. The
immunoblots were normalized using anti-actin antibodies (lower panels). MW molecular weight markers are shown in kDa. e Quantification by
ImageJ of at least three immunoblots from biological replicates as the one shown in panel (c) (cleaved αII-spectrin, black bars) and panel (d) (white
bars) (±SD; N= 3). ***P ≤ 0.001; **P ≤ 0.01; *P ≤ 0.05
Comitato et al. Cell Death and Disease  (2018) 9:560 Page 5 of 13
Official journal of the Cell Death Differentiation Association
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calpains and, in turn, its downstream cell death effectors,
and implied that interaction of amino acid positions
98–114 of PEDF with its receptor PEDF-R were sufficient
for neuroprotection.
Discussion
In this study, we report that PEDF challenges a cell
death pathway in photoreceptor cells that is activated by
increased intracellular Ca2+ in the degenerating rod
photoreceptors bearing a loss-of-function mutation in the
Pde6b gene. Our data demonstrate that this mechanism
of neuroprotection is specifically mediated via the
PEDF–PEDF-R interaction. In fact, the effect was abol-
ished by the blocking PEDF-R peptide (PEDF-R ligand
binding domain, P1 peptide). We also showed that the 17-
mer and 17-mer[H105A] domains of PEDF, which bind
PEDF-R, recapitulate the survival effect on degenerating
photoreceptor cells like PEDF. Together with the absence
of any survival effect by 17-mer[R99A], lacking binding
affinity for PEDF-R, these observations further demon-
strate that the PEDF neuroprotection activity on rd1
photoreceptors is mediated by direct and specific inter-
actions with PEDF-R.
The binding of PEDF, specifically the domain contain-
ing the 17-mer, to PEDF-R on the cells surface activates
intracellular events leading to cell survival (Fig. 6). The
findings demonstrate that PEDF acts on survival via a
calcium-related pathway. In fact, PEDF decreases the
elevated levels of intracellular calcium, as well as the high
calpain activity in rd1 mutant photoreceptors. This effect
is similar to the PEDF-mediated decreases of [Ca2+]i in
cerebellar granule cells exposed to glutamate toxicity,
which have been associated with cell survival47. Interest-
ingly, our data with inhibitors of calcium pumps shed
light on the mechanisms by which PEDF diminishes
intracellular calcium, by implying that PEDF favors cal-
cium efflux, via PMCA, at the level of the plasma mem-
brane and reduces cytoplasmic calcium below toxic levels.
Recent reports demonstrated that PEDF–PEDF-R inter-
actions stimulate the specific release of the omega-3 fatty
acid docosahexaenoic acid (DHA) from phospholipids by
the phospholipase A2 activity of PEDF-R31,48. It is worth
noting that DHA can prevent Ca2+ overload by favoring
PMCA function for Ca2+ efflux and by interfering L-type
Ca2+ channels for Ca2+ entrance, shown both in cardio-
myocytes49,50. On the one hand, we conclude that upon
binding to the receptor, PEDF enhances its PLA2 activity
to liberate DHA that targets PCMA favoring calcium
efflux. At this time, we cannot exclude the effects on
the L-type Ca2+ channel of DHA generated by the
PEDF–PEDF-R interaction, which would be in agreement
with our previous observations that blocking of this type
of channels reduces photoreceptor cell death in the rd1
mutant retina37. On the other hand, the effects of PEDF/
PEDF-R on Ca2+ may also be mediated by the increase of
BCL2, given that BCL2 modulates fluxes of Ca2+ in other
systems51. Altogether, these observations suggest an effect
of PEDF on intracellular targets preventing Ca2+ overload
in rd1 mutant photoreceptor cells.
As far as we know, this is the first time that a PEDF-
mediated decrease in calpain activity is demonstrated. The
neuroprotective effects of PEDF targeting intracellular
calcium correlate with attenuation of the enzymatic
activities of calpains and of cathepsin D, which together
are involved in triggering BAX and AIF cell death
mechanisms2,37. The effect on calpains could again be
mediated by DHA as this fatty acid, a mediator of PEDF
signaling52, could interfere in vitro with calpain activation
in cells stressed by Ca2+ influx53. PEDF also weakens the
cell death pathway involving BAX and AIF. Our data
agree with the report by Murakami et al, in which PEDF
administration in the retina of Royal College of Surgeon
rats upregulates the Bcl2 gene and blocks AIF nuclear
translocation in photoreceptors12. Our previous report on
the protection of PEDF on DKO rd8 (Ccl2-/-/Cx3cr1-/- on
C57BL/6 N [Crb1rd8]) mice, a model for progressive, focal
retinal degeneration, agrees with data in the present study
by showing lower levels of BAX protein, higher levels of
BCL2 protein, decrease in cell death and attenuation of
focal retinal lesions in the PEDF-treated retina20.
In summary, our data highlight the actions of PEDF
and PEDF-based peptides as neuroprotective factors for
photoreceptor cells at early steps during the cell death
cascade thus affecting several molecules correlated to
(see figure on previous page)
Fig. 3 PEDF effects on Cathepsin D, BAX and BCL2. Protein analyses on wild-type (WT) and rd1 mutant mouse retinas treated with either vehicle
(MOCK) or PEDF or PEDF and P1 blocking peptide (PEDF+ P1). a Total protein extracts were analyzed by immunoblot with an anti-cathepsin D
antibody. The antibody recognizes both uncleaved cathepsin D (arrow) and cleaved/activated cathepsin D (asterisk). The immunoblot was
normalized using anti-actin antibodies (lower panel). b Quantification by ImageJ of three immunoblots from biological replicates as the one shown
in panel (a) (±SD; N= 3). White bars show values for uncleaved cathepsin D and gray bars show values for activated/cleaved cathepsin D. c Analysis
of the BAX protein in mitochondria enriched extracts. The immunoblot was normalized with anti-cytochrome c antibodies (lower panel). d
Quantification by ImageJ of three immunoblots from biological replicates as the one shown in panel (c) (±SD; N= 3). e Total protein extracts were
analyzed by immunoblot with an anti-BCL2 antibody. The immunoblot was normalized using anti-actin antibodies (lower panel). f Quantification by
ImageJ of three immunoblots from biological replicates as the one shown in panel (a) (±SD; N= 3). MW molecular weight markers are shown in kDa.
***P ≤ 0.001; *P ≤ 0.05
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photoreceptor cell degeneration. The conclusions
enhance our understanding of the molecular mechanism
underlying the effects of a neurotrophic factor targeting
common cell death mechanisms, which is an attractive
strategy for treating more than one form of the many
types of retinal degenerations.
Materials and methods
Animal care and treatments
All procedures on mice were conducted at CSSI (Centro
Servizi Stabulario Interdipartimentale), approved by the
Ethical Committee of University of Modena and Reggio
Emilia and by the Italian Ministero della Salute (346/
Fig. 4 Effects of PEDF on AIF. a Immunofluorescence of AIF (red) and TUNEL+ staining of dying cells (green) in rd1 mutant retinas treated with
vehicle (MOCK) or PEDF or PEDF and 10 molar excess of P1 peptide (PEDF+ P1). A decrease of double-labeled cells (arrows and yellow in the merged
image) was observed after treatment with PEDF but not with PEDF+ P1. Nuclei are stained in blue with DAPI. Only the outer nuclear layer containing
photoreceptor nuclei is shown. Scale bars: 25 μm. b Histogram representing the percentage (±SD) of photoreceptors showing nuclear localization of
AIF (red) or labeling with TUNEL (green). (N= 4–7; ***P ≤ 0.001). c Immunoblotting of AIF in nuclear-enriched protein extracts from wild-type (WT)
and rd1 mutant mouse retinas after treatment with either vehicle (MOCK) or PEDF or PEDF and P1 blocking peptide (PEDF+ P1). The immunoblot
was normalized with anti-H3 histone antibodies (lower panel). MW molecular weight markers are shown in kDa. d Quantification by ImageJ of three
immunoblots from biological replicates as the one shown in panel (c) (±SD; N= 3; **P ≤ 0.01; *P ≤ 0.05)
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2015-PR) and were in accordance with the ARVO State-
ment for the Use of Animals in Ophthalmic and Vision
Research. C3H/HeN (rd1) mice were purchased from
Envigo Italy (Udine, IT). Mice were maintained in 12-h
light/dark cycles and had free access to food and water.
For intravitreal administration, mice were anesthetized
with an intraperitoneal injection of 250mg/kg body
weight of avertin (1.25% (w/v) 2,2,2-tribromoethanol and
2.5% (v/v) 2-methyl-2-butanol; Sigma, Milan, IT). Subse-
quently, eyes were intravitreously injected via a trans-
scleral trans-choroidal approach with 0.5 μl of PEDF
recombinant protein (6 pmol) or of PEDF recombinant
protein (6 pmol) with 100 μM CLX 3A1 (final intravitreal
concentration; AnaSpec) or of 17-mer (6 pmol) or of 17-
mer[R99A] (6 pmol) or of 17-mer[H105A] (2 pmol) pep-
tides or of PEDF together with 10-fold molar excess of P1
peptide (a peptide from PEDF-R encompassing the PEDF
binding domain)11. Control eyes received vehicle only
(mock injected). Mice were sacrificed 16 h post-injection.
Cell culture and treatments
661W cells, immortalized photoreceptor precursors54,
were generously provided by Dr. Muayyad Al-Ubaidi
(University of Oklahoma) and cultured in high glucose
(4.5 mg/ml) Dulbecco’s modified Eagle's medium
(DMEM) supplemented with 10% fetal bovine serum
(FBS), 2 mM glutamine, 100 U/ml penicillin and 100 µg/
ml streptomycin purchased from Invitrogen (Thermo-
Fisher Scientific). In total, 20,000 cells were seeded onto
glass cover-slips coated with poly-D-lysine. The following
day cells were treated for 2 h with medium containing 10
nM PEDF or an equal volume of phosphate-buffered
saline (PBS) as control and then stressed with 500 μM
zaprinast (Sigma) or 5 μM A23187 (Sigma) for 16 h in the
absence or presence of PEDF. When calcium pump
blockers were used, 100 μM BZ (Tocris) or 10 μM CLX
(AnaSpec) or 200 nM TG (Sigma) were added. Cells were
fixed with 2% paraformaldehyde (PFA) for 10min at room
temperature.
(see figure on previous page)
Fig. 5 Neuroprotective activity of 17-mer peptides. Markers of the cell death pathways were analyzed in rd1 mutant retinas after exposure to
vehicle (MOCK) or 17-mer or 17-mer[H105A] (H105A) or 17-mer[R99A] (R99A). a Histogram representing the percentage of photoreceptors labeled by
the fluorescent calpain activity assay (N= 4; ± SD; ***P ≤ 0.001). b αII-spectrin was analyzed by immunoblot in total protein extracts from mouse
retinas. The 145–150 kDa fragments resulting from calpain cleavage are marked by an asterisk. The immunoblot was normalized using anti-actin
antibodies (lower panel) (N= 3). c Immunoblotting of BAX protein in mitochondria enriched protein extracts. The immunoblot was normalized with
anti-cytochrome c antibodies (lower panel) (N= 3). d Total protein extracts were analyzed by immunoblot with an anti-BCL2 antibody. The
immunoblot was normalized using anti-actin antibodies (lower panel) (N= 3). e Histogram representing the percentage of photoreceptors labeled
with TUNEL (black) or by nuclear localization of AIF (white) (N= 4; ± SD; ***P ≤ 0.001). f Immunoblotting of AIF protein in nuclear-enriched protein
extracts. The immunoblot was normalized with anti-H3 histone antibodies (lower panel) (N= 3)
Fig. 6 Scheme on the mechanism mediating PEDF promotion of photoreceptor survival. a Cell death pathway in rd1 photoreceptors is
associated with high [Ca2+]i, activation of calpain (Calpaina), Cathepsin D (Cat Da) and BAX, as well as of translocation of AIF from the mitochondria to
the nucleus. b PEDF, or the 17-mer peptide, binds to PEDF-R and stimulates its PLA2 activity to release DHA from phospholipids (P1 peptide can
interfere with the binding of PEDF to PEDF-R). DHA decreases [Ca2+]i through PMCA activity (Ca
2+ extrusion). Decreased [Ca2+]i is associated with
inactivation of calpain (Calpaini) and Cathepsin D (Cat Di), blockage of mitochondrial translocation of BAX and nuclear translocation of AIF, as well as
increase in BCL2 levels, all of which contribute to cell survival in the rd1 mouse photoreceptors
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Retinal neurospheres were generated from rd1 mutant
eyes and differentiated into rod-like cells as previously
published37. Cells were exposed to 10 nM PEDF or 10 nM
PEDF with 10 μM CLX or an equal volume of PBS as
control at 10 days of culture in differentiation medium
(1 day before the peak of cell death37). Eighteen hours
after treatment, cells were fixed with 2% PFA for 10min.
Either 661W cells or primary rod-like cells underwent
TUNEL assay or Fluo-4 AM staining, as described below.
Nuclei were stained with 0.0005% 4′,6-diamidino-2-phe-
nylindole (DAPI; Molecular Probes). Slides were mounted
with Mowiol 4–88 (Sigma), images were taken using a
Zeiss Axio Imager A2 microscope and TUNEL+ and
DAPI-stained nuclei were counted to calculate percentage
of cell death.
Cytofluorimetric analysis of calcium
Intracellular calcium levels were determined with the
intracellular calcium probe Fluo-4 AM (Life Technolo-
gies), as previously published55. Briefly, retinas were har-
vested and incubated in 19 U/ml papain for 30 min and,
after 33-fold dilution with DMEM containing 10 U/ml
DNAse, retina cells were dissociated by trituration. After
three washes with PBS, cells were incubated with 0.5 μM
Fluo-4 AM at 37 °C for 30min in Ca2+-free medium.
Fluorescence was measured with a Coulter Epics XL-MCL
flow cytometer (Beckman Coulter) at an excitation
wavelength of 488 nm and Fluo-4 AM median fluores-
cence intensity (MFI) was calculated. Photoreceptor cells
were characterized by co-staining with anti-Rhodopsin
antibody 1D4 (1:1000, Sigma) and anti-Recoverin (1:500,
Millipore) as described before56 and plotted over the
forward scatter to define the gating strategy for the fol-
lowing intracellular calcium analysis (Supplemental fig-
ure S1 a and b). Fluo-4 AM signal was measured in at least
four different rd1 retinas treated with PEDF and the
percentages of cells with high fluorescence were com-
pared with contralateral rd1 retinas either mock-treated
or treated with PEDF and 10-fold molar excess of P1
peptide. The ratios are presented as means ± SD of 4–8
biological replicates.
Cytofluorimetric analysis of calcium in 661W cells was
performed as in Wyse-Jackson et al.57. Briefly, cells were
stained with 1 μM Fluo-4 AM at 37 °C for 30min in Ca2
+-free medium Hank’s Balanced Salt solution (HBSS,
Thermofisher) in the dark. After incubation, cells were
washed twice with PBS. Cell were detached by treatment
with AccutaseTM (Millipore) and resuspended in 10%
HBSS, 1 mM CaCl2, 1 mM MgCl2, 1% FBS. Finally, cells
were washed in annexin binding buffer and incubated 10
min with annexin V conjugated with Pacific Blue (Ther-
mofisher) and the TO-PRO™3 Ready Flow™ Reagent
(Thermofisher) was added just before the acquisition
according to standard procedures. Cells were acquired by
using an Attune NxT Acoustic flow cytometer (Ther-
mofisher) equipped with four lasers (405 nm, 488 nm, 561
nm, 634 nm). Living cells (TO-PRO-Annexin V−) were
gated (Supplemental figure S1 e), and Fluo-4 AMMFI was
calculated on such cells.
Calpain activity assay
Cryosections from unfixed retinas of at least three mice
were incubated for 15min in calpain reaction buffer
(CRB: 25 mM HEPES-KOH pH 7.2, 65 mM KCl, 2 mM
MgCl2, 1.5 mM CaCl2, 2 mM DTT), as previously
described9, and then exposed for 1 h at 37 °C to the
fluorescent calpain substrate CMAC, t-BOC-Leu-Met
(A6520, Invitrogen) at a final concentration of 2 µM.
Slides were washed twice for 10min each in CRB,
mounted with mowiol 4–88 (Sigma) and analyzed at a
Zeiss Axio Imager A2 microscope using the filter excita-
tion/emission 365/420. Labeled cells were counted in the
outer nuclear layer (ONL) containing photoreceptors in at
least three entire sections passing through the optic nerve
from three independent experiments.
DNA nick-end labeling by TUNEL and immunofluorescence
Eyes were oriented, fixed in Davidson’s fixative (8%
Formaldehyde, 31.5% Ethanol, 2M Acetic Acid), embed-
ded in paraffin and sectioned as previously described37.
Apoptotic nuclei were detected by TUNEL kit (fluor-
escein; Roche) according to the producer’s protocols.
Primary antibodies were used as follows: anti-AIF (1:100;
Sigma), anti-phosphorylated PERK (1:100, Cell Signaling),
anti-RHO (1D4 1:250; Sigma), anti-BAX 6A7 (1:200, BD
Biosciences), anti-BCL2 (1:100, Cell Signaling) and anti-
calpastatin (1:100, Cell Signaling). Secondary antibodies
were Alexa Fluor® 568 anti-mouse and anti-rabbit anti-
bodies (1:1000, Molecular Probes). Slides were mounted
with mowiol 4–88 (Sigma) and analyzed at a Zeiss Axio
Imager A2 microscope. Quantification of dying cells was
performed by counting all TUNEL labeled cells in the
photoreceptor cell layer passing through the optic nerve
in at least three sections from different animals. The
number of photoreceptors was counted by staining of
nuclei with DAPI and was used to calculate percentage of
dying cells.
Retinal protein extracts and western blotting analysis
Retinas were lysed as previously described to obtain
nuclear-enriched proteins and mitochondrial-enriched
proteins2. The purity of enriched lysates was checked by
immunoblotting using a nuclear marker (anti-Histone H3
1:3000; Bethyl Laboratories), a mitochondrial marker
(anti-cytochrome c, 1:2000, BD Biosciences) or a cytosol
marker (anti-pan-actin, 1:3000, Millipore).
Equivalent amounts of protein extracts (20 μg) were
resolved using sodium dodecyl sulfate–polyacrylamide gel
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electrophoresis and immunoblottings were performed
following standard procedures. The antibodies used for
western blotting were: anti-αII-spectrin (1:2000, Enzo
Life), anti-AIF (1:1000, Calbiochem), anti-BAX 6A7
(1:2000, BD Biosciences), anti-BCL2 (1:2000, Cell Signal-
ing), anti-calpastatin (1:1000, Cell Signaling), anti-
cathepsin D (C-20 1:1000, Santa Cruz Biotechnology).
Quantification was performed by densitometry analysis of
scanned images with the ImageJ software, corrected by
background and plotted as protein/normalizing protein.
Data are presented as means ± SD of three blots. Each blot
analyzed proteins derived from four retinas pooled toge-
ther and three independent pools from three different
litters were used as biological replicates.
Statistical analysis
Cell counts and densitometry analyses are shown as
mean ± SD. Student’s t-test analysis was performed to
compare data derived from at least three different mock-
treated mutant retinas or retinas co-treated with PEDF
and 10-fold molar excess of P1 peptide to at least three
different contralateral PEDF-treated mutant retinas.
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Figure S1. Flow cytofluorimetric analyses of calcium. (a) Flow cytometric characterization of 
photoreceptor cels dissociated from a PN12 rd1 mutant retina. Shown are the analyses of the cel 
population and of the rod photoreceptor cels labeled with the anti-Rho antibody (Y axis, RHO) and 
anti-recoverin (X axis, REC). This photoreceptor population was gated for studies shown in figure 1 a 
and b. (b) Flow cytometry unstained controls of the cel population and of the secondary antibodies 
(FITC = fluorescein; APC = Alophycocyanin) used for analyses shown in panel a. (c) Flow cytofluorimetry 
outcomes of calcium labeling with Fluo-4 AM (fluorescence intensity on the Y axis) in rd1 retinas at PN12 
either mock injected or injected with PEDF. Cel with high level of Ca2+ were measured by gating as 
shown in the figure. The percentage values retrieved by the gating were used to calculate ratios shown in 
figure 1b. The background fluorescence in samples not treated with Fluo-4 AM (no Fluo-4 AM) is shown in 
the panel at the left-hand side. (d) Flow cytofluorimetry outcomes of calcium labeling with Fluo-4 AM 
(fluorescence intensity on the Y axis) in rd1 retinas at PN12 either injected with P1 alone or co-injected 
with PEDF and P1 blocking peptide or injected with PEDF. The gates applied measured cels with high 
level of Ca2+ and these values were used to calculate ratios shown in figure 1b. (e) Characterization of the 
cel population used for cytofluorimetric analysis of 661W cels. Only non-apoptotic cels, negative to 
TO-PRO3 and annexin-V staining (lower left quadrant in the figure), were analyzed for calcium content 
shown in figure 1c.
Figure S2. Efects of calcium pump blockers in 661W photoreceptor cels. (a) 661W cels stressed 
with 500 μM zaprinast (ZAP) showed increased intracelular Ca2+ by staining with Fluo-4 AM (green in 
left-hand side panels) and cel death (TUNEL, green in right-hand side panels) when compared to not 
treated cels (NT). PEDF (ZAP+PEDF) reduced intracelular Ca2+ (left-hand side panels) and cel death 
(right-hand side panels). (b) 661W cels were treated for 16 hours with either 100 μM 3',4'-dichlorobenza-
myl (BZ) or 10 μM caloxin (CLX). The blocking efects of BZ and CLX on the pumps was demonstrated by 
increased intracelular Ca2+ visualized by Fluo-4 AM staining (green signal). (c) The efect of 200 nM 
thapsigargin (TG) was assessed by analysis of activation of the ER-stress sensor PERK that was found 
phosphorylated (red signal). (d) 611W cels were treated for 16 hours with 5 μM A23187, an ionophore 
that alows calcium influx. Influx of Ca2+ induced cel death in about 20% of the cels. Exposure to 10 nM 
PEDF reduced cel death by 84%. When cels were co-treated with the calcium pump blocker caloxin 
(CLX, 10 μM), PEDF neuroprotective efects were almost lost with a remaining neuroprotection of 18%. 
Data are shown as means ±SD (N=3; *** P≤0.001).
Figure S3. PEDF protects primary rd1 mutant rod-like cels against cel death by acting on PMCA. 
(a) Retinal neurospheres were generated from rd1 mutant ciliary epithelium and alowed to diferentiate 
into rod-like cels for 11 days. At day 10 of diferentiation, cels were exposed to 10 nM PEDF or to PBS as 
control (rd1 NT) or to 10 μM caloxin (CLX) or to 10 nM PEDF and 10 μM caloxin (PEDF+CLX). Eighteen 
hours later cels were fixed and analyzed for intracelular Ca2+ with Fluo-4 AM (green, upper panels) and 
for cel death (red, lower panels) and rhodopsin expression (RHO green, lower panels). PEDF decreased 
intracelular Ca2+ and cel death. (b) PEDF (10 nM) recovered cel death by 42% of primary rd1 mutant 
rod-like cels. PEDF neuroprotection was lost when cels were exposed to 10 μM caloxin (CLX). 
Data are shown as means ±SD (N=6; *** P≤0.001).
Figure S4. Efects of diferent caloxin concentrations in vivo in degenerating retinas. Eyes were 
intravitrealy injected with 10 or 100 or 1000 μM caloxin at PN11 and analyzed at PN12. (a) The levels of 
calcium (medium fluorescence intensity, MFI) was analyzed by Fluo-4 AM in photoreceptor cels (events), 
characterized as described in supplemental figure S1. Significant increase of calcium was detected 
starting from treatments with 100 μM of caloxin, suggesting that this concentration was suficient to afect 
PMCA pumps in photoreceptor cels in vivo. (b) Photoreceptor cel death was evaluated in sections of 
treated retinas and the concentration of 100 μM of caloxin induced less than 1% of cel death in 
photoreceptors. 
Figure S5. Efects of PEDF on Calpastatin, BCL2 and BAX. (a) Calpastatin was evaluated by 
immunofluorescence (red). Decreased Calpastatin was detected in rd1 mock treated retina (MOCK) 
compared to wild type retina (WT). Nuclei were stained with DAPI (blue). No change was detected after 
treatment with PEDF (PEDF) or PEDF and P1 blocking peptide (PEDF+P1). (b) Activation of BAX was 
detected with the anti-activated-BAX specific antibody (red) at the inner segment (containing cytoplasm, 
mitochondria and ER of photoreceptor cels) of rd1 treated mutant retinas (MOCK; arow). No staining 
with the antibody for activated BAX was detectable in wild type retina (WT) at P12. Fluorescent staining 
was reduced after treatment with PEDF (arow) but not after treatment with PEDF and P1 blocking peptide 
(PEDF+P1; arow). (c) BCL2 was evaluated by immunofluorescence (red). Nuclei were stained with DAPI 
(blue). Decreased BCL2 was detected in rd1 mock treated retina (MOCK) compared to wild type retina 
(WT). Recovery of BCL2 was detectable after treatment with PEDF (PEDF) but not in retinas treated with 
PEDF and P1 blocking peptide (PEDF+P1). Micrographs in panels a, b and c show the outer nuclear layer 
containing photoreceptor cels (white bars). Scale bar in panels a, b and c: 20μm. (d) rd1 mutant retina 
section stained with antibodies anti-AIF (red), TUNEL assay (green) and DAPI (blue). Confocal xy-planes 
and the z-stack are shown. Red, green and blue fluorochromes label the selected dying cel, as shown at 
the right-hand side. Fluorescence of the three channels along the horizontal line passing through the 
same co-labeled cel is shown below the micrograph. The outer nuclear layer, containing photoreceptor 
nuclei, is indicated by a white bar.
